Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Best Practice & Research. Clinical Haematology
|
November 29, 2015
The importance of the tissue microenvironment in hairy cell leukemia
Mariela Sivina, Jan A Burger
Leukemia & Lymphoma
|
March 29, 2011
The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets
Jan A Burger, Mariela Sivina, Farhad Ravandi
British Journal of Haematology
|
April 5, 2014
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach
Mariela Sivina, Robert J Kreitman, Evgeny Arons, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
February 26, 2011
The transcription factor E74-like factor controls quiescence of endothelial cells and their resistance to myeloablative treatments in bone marrow
Mariela Sivina, Takeshi Yamada, Chun Shik Park, et al.
Cancer Cell
|
March 15, 2006
The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells
H Daniel Lacorazza, Takeshi Yamada, Yan Liu, et al.
Leukemia & Lymphoma
|
July 30, 2019
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia
Leslie A Andritsos, John C Byrd, Peter Cheverton, et al.
Blood
|
June 4, 2009
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
Maite P Quiroga, Kumudha Balakrishnan, Antonina V Kurtova, et al.
British Journal of Haematology
|
April 14, 2016
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia
Shubhchintan Randhawa, Byung S Cho, Dipanjan Ghosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2016
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Preetesh Jain, Michael J Keating, William G Wierda, et al.
Blood
|
March 1, 2019
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia
Pablo Elías Morande, Mariela Sivina, Angimar Uriepero, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Best Practice & Research. Clinical Haematology
|
November 29, 2015
The importance of the tissue microenvironment in hairy cell leukemia
Mariela Sivina, Jan A Burger
Leukemia & Lymphoma
|
March 29, 2011
The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets
Jan A Burger, Mariela Sivina, Farhad Ravandi
British Journal of Haematology
|
April 5, 2014
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach
Mariela Sivina, Robert J Kreitman, Evgeny Arons, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
February 26, 2011
The transcription factor E74-like factor controls quiescence of endothelial cells and their resistance to myeloablative treatments in bone marrow
Mariela Sivina, Takeshi Yamada, Chun Shik Park, et al.
Cancer Cell
|
March 15, 2006
The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells
H Daniel Lacorazza, Takeshi Yamada, Yan Liu, et al.
Leukemia & Lymphoma
|
July 30, 2019
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia
Leslie A Andritsos, John C Byrd, Peter Cheverton, et al.
Blood
|
June 4, 2009
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
Maite P Quiroga, Kumudha Balakrishnan, Antonina V Kurtova, et al.
British Journal of Haematology
|
April 14, 2016
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia
Shubhchintan Randhawa, Byung S Cho, Dipanjan Ghosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2016
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Preetesh Jain, Michael J Keating, William G Wierda, et al.
Blood
|
March 1, 2019
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia
Pablo Elías Morande, Mariela Sivina, Angimar Uriepero, et al.
Page
of 3